Heplisav-B
Selected indexed studies
- CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. (Expert Rev Vaccines, 2021) [PMID:33783302]
- Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series. (Mil Med, 2022) [PMID:34557923]
- Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. (Drugs Today (Barc), 2018) [PMID:30090877]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. (2021) pubmed
- Heplisav-B in Prior Hepatitis B Vaccine Nonresponders: A Case Series. (2022) pubmed
- Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States. (2018) pubmed
- Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant. (2021) pubmed
- Seroconversion following Heplisav-B, hepatitis B vaccine (recombinant), adjuvanted, in patients with end-stage renal disease at an urban safety net hospital. (2023) pubmed
- Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers. (2025) pubmed
- Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B. (2021) pubmed
- Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience. (2021) pubmed
- High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease. (2025) pubmed
- Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. (2021) pubmed